Drug Makers Stock Performance Review -- Alliqua BioMedical, Aerie Pharma, Shire, and Heron Therapeutics

NEW YORK, July 26, 2017 /PRNewswire/ --

If you want a Stock Review on ALQA, AERI, SHPG, or HRTX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com revisits the Major Drug Manufacturers space, which is engaged in the development and sale of medicines and vaccines for a wide range of medical uses. Most drug manufacturers are structured as corporations, and many of these companies offer slightly higher-than-average dividend yields. Equities to assess this morning are: Alliqua BioMedical Inc. (NASDAQ: ALQA), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Shire PLC (NASDAQ: SHPG), and Heron Therapeutics Inc. (NASDAQ: HRTX). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at: http://dailystocktracker.com/register/

Alliqua BioMedical 

Yardley, Pennsylvania-based Alliqua BioMedical Inc.'s stock finished Tuesday's session 2.56% higher at $0.36 with a total trading volume of 264,944 shares. Over the last month, the Company's shares have advanced 12.99%. The stock is trading below its 50-day moving average by 2.95%. Moreover, shares of Alliqua BioMedical, which commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue, have a Relative Strength Index (RSI) of 46.41. Your complete research report on ALQA can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=ALQA

Aerie Pharma 

Shares in Irvine, California-based Aerie Pharmaceuticals Inc. declined 2.86%, ending yesterday's session at $55.95 with a total trading volume of 348,425 shares. The stock has gained 2.10% in the past month, 32.27% in the previous three months, and 47.82% on an YTD basis. The Company's shares are trading 8.23% above their 50-day moving average and 27.15% above their 200-day moving average. Moreover, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have an RSI of 53.30.  

On July 19^th, 2017, Aerie Pharma reported the successful 12-month safety results of the Company's "Mercury 1" Phase-3 registration trial for its fixed-dose combination product candidate, Roclatan™. Mercury 1 is a 12-month safety and efficacy trial, which included a 90-day efficacy endpoint. There were no new adverse events that developed following the initial 90-day period, and there were no drug-related serious or systemic adverse events.

On July 20^th, 2017, research firm Cantor Fitzgerald reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $56 a share to $62 a share. A free report on AERI is just a click away at: http://dailystocktracker.com/registration/?symbol=AERI

Shire 

On Tuesday, Dublin, Ireland headquartered Shire PLC's stock rose 1.51%, to close the day at $166.11. A total volume of 1.22 million shares was traded. The Company's shares are trading 2.99% below their 50-day moving average. Additionally, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have an RSI of 47.07.  

On July 18^th, 2017, Shire announced that it will report Q2 2017 earnings on August 03^rd, 2017. Results of the press release will be issued at 7:00 EDT on the same day, followed by an investor and analyst conference call at 9:00 EDT. Flemming Ornskov, MD, CEO, and Jeff Poulton, CFO, will host the call. Sign up for your complimentary research report on SHPG at: http://dailystocktracker.com/registration/?symbol=SHPG

Heron Therapeutics 

Shares in Redwood City, California headquartered Heron Therapeutics Inc. ended the day 1.18% higher at $17.10. A total volume of 550,748 shares was traded. The stock has gained 13.62% in the last one month, 12.13% in the previous three months, and 30.53% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 18.24% and 16.48%, respectively. Furthermore, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 63.77. Register for free on DailyStockTracker.com and download the latest research report on HRTX at: http://dailystocktracker.com/registration/?symbol=HRTX

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA